Department of Microbiology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, United States.
Cancer Lett. 2013 Sep 10;338(1):158-67. doi: 10.1016/j.canlet.2012.05.028. Epub 2012 May 29.
Osteosarcoma is an aggressive pediatric tumor of growing bones that, despite surgery and chemotherapy, is prone to relapse. These mesenchymal tumors are derived from progenitor cells in the osteoblast lineage that have accumulated mutations to escape cell cycle checkpoints leading to excessive proliferation and defects in their ability to differentiate appropriately into mature bone-forming osteoblasts. Like other malignant tumors, osteosarcoma is often heterogeneous, consisting of phenotypically distinct cells with features of different stages of differentiation. The cancer stem cell hypothesis posits that tumors are maintained by stem cells and it is the incomplete eradication of a refractory population of tumor-initiating stem cells that accounts for drug resistance and tumor relapse. In this review we present our current knowledge about the biology of osteosarcoma stem cells from mouse and human tumors, highlighting new insights and unresolved issues in the identification of this elusive population. We focus on factors and pathways that are implicated in maintaining such cells, and differences from paradigms of epithelial cancers. Targeting of the cancer stem cells in osteosarcoma is a promising avenue to explore to develop new therapies for this devastating childhood cancer.
骨肉瘤是一种侵袭性的儿童期骨肿瘤,尽管进行了手术和化疗,但仍容易复发。这些间叶性肿瘤来源于成骨细胞系中的祖细胞,这些祖细胞积累了突变,从而逃避细胞周期检查点,导致过度增殖,并使其分化为成熟的成骨细胞的能力出现缺陷。与其他恶性肿瘤一样,骨肉瘤通常是异质性的,由具有不同分化阶段特征的表型不同的细胞组成。癌症干细胞假说认为,肿瘤是由干细胞维持的,正是由于难以消除具有肿瘤起始能力的耐药性干细胞群体,导致了耐药性和肿瘤复发。在这篇综述中,我们介绍了来自小鼠和人类肿瘤的骨肉瘤干细胞生物学的现有知识,强调了在鉴定这种难以捉摸的细胞群体方面的新见解和未解决的问题。我们重点介绍了维持这些细胞的相关因素和途径,以及与上皮性癌症模式的差异。针对骨肉瘤中的癌症干细胞是探索开发这种毁灭性儿童癌症新疗法的一个有前途的途径。